Skip to content

Liposomal Bupivacaine vs. Bupivacaine Hydrochloride and Lidocaine During Suburethral Sling Placement

Liposomal Bupivacaine vs. Bupivacaine Hydrochloride and Lidocaine During Suburethral Sling Placement: a Randomized Control Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02875015
Enrollment
57
Registered
2016-08-23
Start date
2016-04-30
Completion date
2018-05-31
Last updated
2018-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Anesthetics, Anesthetic Effects, Mid-urethral sling

Brief summary

Postoperative pain, the quality of their recovery and the opioid consumption following a midurethral sling placement are being compared between 2 groups. One group will have the hydro-dissection performed with a diluted liposomal bupivacaine solution. The other group will have the hydro-dissection performed with a diluted bupivacaine HCL and Lidocaine solution.

Detailed description

This is a prospective, comparative, randomized study. Women with pure stress urinary incontinence or mixed urinary incontinence with a predominant stress component who had chosen to proceed with a midurethral sling will be randomized to two groups. The study group will have the hydro-dissection performed with a diluted liposomal bupivacaine solution. The comparison group would have the hydro-dissection performed with a diluted bupivacaine HCL and Lidocaine solution. The postoperative pain will be compared between groups using a visual analog scale. The quality of recovery will be compared between the groups using the quality of recovery short form. Postoperative opioid consumption will be compared between the two groups.

Interventions

DRUGLiposomal Bupivacaine

20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars

DRUGBupivacaine Hydrochloride and Lidocaine

Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.

PROCEDURESuburethral Sling

A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.

Sponsors

Atlantic Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* ASA physical status I-III * Age \>18 years * Not Pregnant * Able to give informed consent * Electively chose surgical management of SUI with a suburethral sling

Exclusion criteria

* Pregnant or nursing * Allergy to amide anesthetics * History of drug or alcohol abuse * Severe cardiovascular, hepatic, renal disease or neurological impairment, * Long-acting opioid within 3 days or any opioid use within 24 hours before surgery * Patients taking monoamineoxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types * Contraindication to: Acetaminophen, Non-steroidal anti-inflammatory drugs (NSAID), Hydrocodone, Oxycodone, Hydromorphone AND Morphine, * Administration of an investigational drug within 30 days before this study * Chronic pain syndromes * Daily NSAID or opioid use * Patients undergoing concomitant procedures

Design outcomes

Primary

MeasureTime frameDescription
Postoperative Day 1 PainPatient will record her average pain on postop day 1. She will return this result at her postop visit 4-6 weeks after her surgery. These results will be examined and compared at the completion of the study.Average pain rating experienced on postoperative day one using the visual analog scale (VAS) on scale of 0 to 10 cm. This will be recorded by the patient prior to going to bed.

Secondary

MeasureTime frameDescription
Postoperative Pain Upon DischargeThe PACU nurse will record the patient's pain level upon discharge to home. These results will be examined and compared at the completion of the study.Visual analog scale (VAS) on scale of 0 to 10 cm will be used to evaluate the pain score experienced upon discharge from the hospital.
Postoperative Pain Four Hours After DischargeRecord the average pain 4 hours after discharge to home. She will return this result at her postop visit 4-6 weeks after her surgery. These results will be examined and compared at the completion of the study.Visual analog scale (VAS) on scale of 0 to 10 cm will be used to evaluate the pain score experienced. This will be recorded 4 hours after being discharged from the hospital.
Night of Surgery Postoperative PainPt will record her average pain on the night of surgery. She will return this result at her postop visit which is approximately 4-6 weeks after her surgery. These results will be examined and compared at the completion of the study.Visual analog scale (VAS) on scale of 0 to 10 cm will be used to evaluate the pain score experienced that day and recorded prior to going to bed on the night of surgery.
Second Stage PACU Postoperative PainThe PACU nurse will record the patient's pain level upon admission to second stage PACU. These results will be examined and compared at the completion of the study.Visual analog scale (VAS) on scale of 0 to 10 cm will be used to evaluate the pain score experienced upon admission to second stage PACU.
Preoperative Quality of RecoveryThe patient will complete the questionnaire prior to surgery. This will be collected prior to surgery. These results will be examined and compared at the completion of the study.Baseline Quality of Life and Recovery as measured by the ambulatory QoR15 preoperatively on the day of surgery.
Postoperative Days 1, 7 and 14 Quality of RecoveryThe patient will complete the questionnaire on postop days 1, 7 & 14. She will return these results at her postop visit 4-6 weeks after her surgery. These results will be examined and compared at the completion of the study.Quality of Life and Recovery as measured by the ambulatory QoR15 on postoperative days 1, 7 and 14.
Postoperative Narcotic ConsumptionThe patient will record narcotic consumption each day from the day of surgery to postop day 7. She will return this result at her postop visit 4-6 weeks after her surgery. These results will be examined and compared at the completion of the study.The total amount of narcotic taken the night of surgery and each day thereafter through postoperative day seven will be recorded each night prior to going to bed.
Postoperative Days 2 through 7 PainPt will record her average pain from postop days 2-7. She will return this result at her postop visit 4-6 weeks after her surgery. These results will be examined and compared at the completion of the study.Visual analog scale (VAS) on scale of 0 to 10 cm will be used to evaluate the pain score experienced that day and recorded prior to going to bed on postop days 2-7.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026